HSV-2 Vaccine Study

Now Enrolling in Cleveland, Grand Island, and Norfolk

Now Enrolling

About this research study

Herpes simplex virus (HSV) is a common infection that can cause painful blisters or ulcers. It primarily spreads by skin-to-skin contact. Symptoms of the virus can include painful, recurring blisters or ulcers. New infections may cause fever, body aches, and swollen lymph nodes while recurrent episodes may begin with tingling, itching, or burning where sores will appear. Herpes is treatable, but there is no cure.

Velocity is now seeking participants for an investigational mRNA genital herpes vaccine study.

Eligible participants...

  • Must be age 18 to 55
  • Must have a diagnosis of genital HSV-2 infection for at least 1 year
  • Must have a history of recurrent genital herpes of at least 3 and less than 10 reported recurrences in the past year
  • Will receive compensation for study-related time and travel

For more information, complete the form on this page. After you submit your information, a Velocity enrollment specialist will call you to talk about the study. There is no obligation to participate — you can decide if the study is right for you.

Enter your info

Study Locations

Cleveland, Ohio • Velocity Clinical Research

3619 Park East Dr., Suite 300, Beachwood, OH 44122
Phone: (216) 682-0320

Grand Island, Nebraska • Velocity Clinical Research

3537 West 13th St., Ste. 100, Grand Island, NE 68803
Phone: (308) 365-8900

Norfolk, Nebraska • Velocity Clinical Research

3400 W Norfolk Avenue, Norfolk, NE 68701
Phone: (402) 371-0797

©2023 Velocity Clinical Research | All Rights Reserved | Privacy Policy